구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-PD1 armored CD19 CAR-T cells (Anti-PD1 armored CD19 CAR-T cells) Jiangsu Topcel-KH Pharmaceutical C…·CD19 1 trials |
|---|---|
Overview Program | Anti-PD1 armored CD19 CAR-T cells |
Overview Company | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Diffuse Large B Cell Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | A Bidirectional EF1 Promoter System for Armoring CD19 CAR-T Cells with Secreted Anti-PD1 Antibodies.. Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies is often limited by T cell exhaustion, which is frequently driven by the PD-1/PD-L1 immune checkpoint axis. To overcome this, we developed an "armored" CAR-T cell strategy using a novel bidirectional promoter system. We enginee… |
Clinical Safety signal | A Bidirectional EF1 Promoter System for Armoring CD19 CAR-T Cells with Secreted Anti-PD1 Antibodies.. Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies is often limited by T cell exhaustion, which is frequently driven by the PD-1/PD-L1 immune checkpoint axis. To overcome this, we developed an "armored" CAR-T cell strategy using a novel bidirectional promoter system. We enginee… |
Clinical Program phase | PHASE_1 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-PD1 armored CD19 CAR-T cells (Anti-PD1 armored CD19 CAR-T cells) Jiangsu Topcel-KH Pharmaceutical C…·CD19 1 trials |
|---|---|
Overview Program | Anti-PD1 armored CD19 CAR-T cells |
Overview Company | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Diffuse Large B Cell Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | A Bidirectional EF1 Promoter System for Armoring CD19 CAR-T Cells with Secreted Anti-PD1 Antibodies.. Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies is often limited by T cell exhaustion, which is frequently driven by the PD-1/PD-L1 immune checkpoint axis. To overcome this, we developed an "armored" CAR-T cell strategy using a novel bidirectional promoter system. We enginee… |
Clinical Safety signal | A Bidirectional EF1 Promoter System for Armoring CD19 CAR-T Cells with Secreted Anti-PD1 Antibodies.. Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies is often limited by T cell exhaustion, which is frequently driven by the PD-1/PD-L1 immune checkpoint axis. To overcome this, we developed an "armored" CAR-T cell strategy using a novel bidirectional promoter system. We enginee… |
Clinical Program phase | PHASE_1 |
추천 비교
추천 비교